npj Breast Cancer
npj Breast Cancer is a journal indexed in SJR in Oncology and Radiology, Nuclear Medicine and Imaging with an H index of 54. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 2790 €. The scope of the journal is focused on biophysics of cancer, metastasis, histopathology, secondary neoplasm occurrence, carcinogenesis, tumour microenvironment. It has an SJR impact factor of 2,968 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,968.
Unclaimed profile — some fields may be incomplete.
Metrics
Campos Scimago / CoP — sin series inventadas
SJR Impact
2,968
H-index
54
Docs (year)
104
Docs 3y
376
Total refs
4432
Cites 3y
2486
Citable 3y
363
Cites/Doc 2y
7
Ref/Doc
42.62
Immediate OA
2790 €
Embargoed OA
NPD
Non OA / Submission
- €
Name good journals. Call out predatory ones.
Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.
Researcher reviews
Best articles by citations
Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy
Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study
The WISDOM Study: breaking the deadlock in the breast cancer screening debate
Inflammatory breast cancer: a model for investigating cluster-based dissemination
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration
Integrated radiomic framework for breast cancer and tumor biology using advanced machine learning and multiparametric MRI
The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk
Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity
The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening
Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype
If we build it they will come: targeting the immune response to breast cancer
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry
Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis
Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry